Agios Pharmaceuticals | AGIO - Sales Revenues


Agios Pharmaceuticals reported $12.9M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Astellas Pharma JPY 571.21B 46.89B Dec/2025
AstraZeneca USD 15.19B 733M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 597.8M 29.5M Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025